摘要
背景:胶质瘤是由中枢神经系统(CNS)的支撑组织胶质细胞产生的脑肿瘤,是最常见的原发性恶性脑肿瘤。胶质瘤分级从一年级到四年级,根据他们在显微镜下的外貌。高级别胶质瘤最显著的不良特征之一是缺氧,这是一种当牛发生的生物学现象。ygen浓度不足以保证正常的组织功能。由于肿瘤缺氧对患者预后有负面影响,靶向性缺氧有潜在的治疗意义。目前人们对测量缺氧的成像技术非常感兴趣。目的:本综述的目的是提供最新的可用于测量低氧I的放射性示踪剂的证据。N脑肿瘤的正电子发射断层扫描(PET),这是研究最广泛的成像方法,以量化缺氧。 方法:以临床前和临床文献为基础,介绍各种有效放射性示踪剂的验证现状。 结果:迄今为止,[F-18]氟硝唑([18F]FMISO)仍然是应用最广泛的放射性示踪剂,用于脑肿瘤患者的低氧显像,但其他放射性示踪剂的使用经验却有所扩大。在过去的二十年里。在这些放射性药物能够广泛用于临床之前,低氧放射性示踪剂的验证仍在进行中,并且是必不可少的。 结论:一种无创成像方法能够可靠地测量和描绘脑肿瘤中不同水平的氧含量,这将为选择患者提供关键的手段。HAT可能受益于针对低氧的量身定做的治疗策略。
关键词: 缺氧,PET,脑肿瘤,胶质瘤,临床前,病人,FMISO,FAZA。
Current Medicinal Chemistry
Title:The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Volume: 25 Issue: 26
关键词: 缺氧,PET,脑肿瘤,胶质瘤,临床前,病人,FMISO,FAZA。
摘要: Background: Gliomas are brain tumours arising from the glia, the supportive tissue of the central nervous system (CNS), and constitute the commonest primary malignant brain tumours. Gliomas are graded from grade I to IV according to their appearance under the microscope. One of the most significant adverse features of high-grade gliomas is hypoxia, a biological phenomenon that develops when the oxygen concentration becomes insufficient to guarantee the normal tissue functions. Since tumour hypoxia influences negatively patient outcome and targeting hypoxia has potential therapeutic implications, there is currently great interest in imaging techniques measuring hypoxia.
Objectives: The aim of this review is to provide up to date evidence on the radiotracers available for measuring hypoxia in brain tumours by means of positron emission tomography (PET), the most extensively investigated imaging approach to quantify hypoxia.
Methods: The review is based on preclinical and clinical papers and describes the validation status of the different available radiotracers.
Results: To date, [F-18] fluoromisonidazole ([18F]FMISO) remains the most widely used radiotracer for imaging hypoxia in patients with brain tumours, but experience with other radiotracers has expanded in the last two decades. Validation of hypoxia radiotracers is still on-going and essential before these radiopharmaceuticals can become widely used in the clinical setting.
Conclusion: Availability of a non-invasive imaging method capable of reliably measuring and mapping different levels of oxygen in brain tumours would provide the critical means of selecting patients that may benefit from tailored treatment strategies targeting hypoxia.
Export Options
About this article
Cite this article as:
The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours, Current Medicinal Chemistry 2018; 25 (26) . https://dx.doi.org/10.2174/0929867324666171116123702
DOI https://dx.doi.org/10.2174/0929867324666171116123702 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Erinacerins, Novel Glioma Inhibitors from <i>Hericium erinaceus</i>, Induce Apoptosis of U87 Cells through Bax/Capase-2 Pathway
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets